Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28166688 | 1.00 | LMNA (0.31) | LMNAKDM4EL3MBTL1 | |
| SCHEMBL28166447 | 1.00 | LMNA (0.31) | LMNAKDM4EL3MBTL1 | |
| SCHEMBL14764013 | 0.83 | TRPA1 (0.32) | — | |
| SCHEMBL22363023 | 0.81 | LMNA (0.30) | LMNA | |
| SCHEMBL3589887 | 0.81 | LMNA (0.48) | LMNA | |
| SCHEMBL1145144 | 0.79 | ALPI (0.42) | — | |
| SCHEMBL7030565 | 0.79 | ALOX5 (0.33) | — | |
| SCHEMBL158756 | 0.78 | LMNA (0.36) | LMNAKDM4E | |
| SCHEMBL21750403 | 0.78 | HRH1 (0.38) | — | |
| SCHEMBL3598843 | 0.78 | AOC3 (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313561-B1 | SUPPORTED CATALYST | BOREALIS TECH OY (FI) | 2006-04-05 | — | — | EP | claimed |
| US-6982238-B2 | Supported catalyst | BOREALIS TECHNOLOGY OY (FI) | 2006-01-03 | — | — | US | claimed |
| US-6887818-B2 | Supported titanium catalyst system | BOREALIS TECHNOLOGY OY (FI) | 2005-05-03 | — | — | US | claimed |
| US-20040014912-A1 | Supported titanium catalyst system | BOREALIS TECHNOLOGY OY (FI) | 2004-01-22 | — | — | US | claimed |
| US-20030166460-A1 | Supported catalyst | BOREALIS TECHNOLOGY OY (FI) | 2003-09-04 | — | — | US | claimed |
| EP-1322676-A2 | SUPPORTED TITANIUM CATALYST SYSTEM | Borealis Technology Oy (FI) | 2003-07-02 | — | — | EP | claimed |
| EP-1313561-A1 | SUPPORTED CATALYST | Borealis Technology Oy (FI) | 2003-05-28 | — | — | EP | claimed |
| WO-2002026837-A2 | SUPPORTED TITANIUM CATALYST SYSTEM | BOREALIS TECHNOLOGY OY (FI) | 2002-04-04 | — | — | WO | claimed |
| WO-2002018046-A1 | SUPPORTED CATALYST | BOREALIS TECHNOLOGY OY (FI) | 2002-03-07 | — | — | WO | claimed |
| CN-110709396-A | Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma | 伊文蒂瓦公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-104470925-A | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2015-03-25 | — | — | CN | disclosed |
| US-7592456-B2 | Arylsulfonylnaphthalene derivatives as 5HT2A antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-1824817-B1 | ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-02-04 | — | — | EP | disclosed |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | MERCK SHARPE & DOHME LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20040014912-A1 | Supported titanium catalyst system | BOREALIS TECHNOLOGY OY (FI) | 2004-01-22 | — | — | US | disclosed |
| US-20030166460-A1 | Supported catalyst | BOREALIS TECHNOLOGY OY (FI) | 2003-09-04 | — | — | US | disclosed |
| EP-1322676-A2 | SUPPORTED TITANIUM CATALYST SYSTEM | Borealis Technology Oy (FI) | 2003-07-02 | — | — | EP | disclosed |
| EP-1313561-A1 | SUPPORTED CATALYST | Borealis Technology Oy (FI) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002026837-A2 | SUPPORTED TITANIUM CATALYST SYSTEM | BOREALIS TECHNOLOGY OY (FI) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002018046-A1 | SUPPORTED CATALYST | BOREALIS TECHNOLOGY OY (FI) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | HTR2A, HTR2C, HTR1A | LMNA 1186/4885KDM4E 4020/4885L3MBTL1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.